OSE Pharma SA (OSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OSE Pharma SA (OSE) has a cash flow conversion efficiency ratio of -0.355x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.98 Million ≈ $-21.02 Million USD) by net assets (€50.60 Million ≈ $59.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can OSE Pharma SA fund operations to measure how many days the company can operate on defensive assets alone.
OSE Pharma SA - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how OSE Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
OSE Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OSE Pharma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dye & Durham Ltd
TO:DND
|
0.002x |
|
Kino Indonesia Tbk PT
JK:KINO
|
0.101x |
|
Forsys Metals Corp.
TO:FSY
|
-0.019x |
|
Fine DNC Co. Ltd
KQ:049120
|
-0.052x |
|
Wonik Corporation
KQ:032940
|
0.005x |
|
Global Lithium Resources Ltd
AU:GL1
|
-0.020x |
|
Power Metals Corp
V:PWM
|
0.001x |
|
Transart Graphics Co Ltd
TW:8481
|
0.068x |
Annual Cash Flow Conversion Efficiency for OSE Pharma SA (2012–2024)
The table below shows the annual cash flow conversion efficiency of OSE Pharma SA from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is OSE Pharma SA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €63.81 Million ≈ $74.60 Million |
€48.44 Million ≈ $56.63 Million |
0.759x | +188.24% |
| 2023-12-31 | €22.98 Million ≈ $26.86 Million |
€-19.76 Million ≈ $-23.11 Million |
-0.860x | -53.40% |
| 2022-12-31 | €32.55 Million ≈ $38.05 Million |
€-18.25 Million ≈ $-21.34 Million |
-0.561x | -168.75% |
| 2021-12-31 | €47.53 Million ≈ $55.57 Million |
€-9.92 Million ≈ $-11.60 Million |
-0.209x | +34.64% |
| 2020-12-31 | €61.24 Million ≈ $71.59 Million |
€-19.55 Million ≈ $-22.86 Million |
-0.319x | -308.16% |
| 2019-12-31 | €58.49 Million ≈ $68.38 Million |
€8.97 Million ≈ $10.49 Million |
0.153x | +779.40% |
| 2018-12-31 | €61.75 Million ≈ $72.20 Million |
€1.08 Million ≈ $1.26 Million |
0.017x | +112.09% |
| 2017-12-31 | €55.45 Million ≈ $64.82 Million |
€-8.00 Million ≈ $-9.35 Million |
-0.144x | -1460.42% |
| 2016-12-31 | €64.53 Million ≈ $75.44 Million |
€684.00K ≈ $799.67K |
0.011x | +103.33% |
| 2015-12-31 | €14.48 Million ≈ $16.92 Million |
€-4.61 Million ≈ $-5.39 Million |
-0.319x | -113.21% |
| 2014-12-31 | €-803.00K ≈ $-938.79K |
€-1.94 Million ≈ $-2.26 Million |
2.412x | +783.11% |
| 2013-12-31 | €-864.00K ≈ $-1.01 Million |
€-236.00K ≈ $-275.91K |
0.273x | -87.59% |
| 2012-12-31 | €-633.00K ≈ $-740.04K |
€-1.39 Million ≈ $-1.63 Million |
2.201x | -- |
About OSE Pharma SA
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more